MODULAR NANOTRANSPORTERS CAPABLE OF BINDING WITH SARS-COV-2 VIRUS NUCLEOCAPSID PROTEIN INTO TARGET CELLS

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Based on the literature data, an antibody-like molecule, a monobody, was selected that is capable of interacting with the nucleocapsid protein (N-protein) of the SARS-CoV-2 virus with high affinity (dissociation constant 6.7 nM). We have previously developed modular nanotransporters (MNTs) to deliver various molecules to a selected compartment of target cells. In this work, a monobody to the N-protein of the SARS-CoV-2 virus was included in the MNT using genetic engineering methods. In this MNT, a site for the cleavage of the monobody from the MNT in endosomes was also introduced. It was shown by thermophoresis that the cleavage of this monobody from MNT by the endosomal protease cathepsin B leads to a 12-fold increase in the affinity of the monobody for the N-protein. Cellular thermal shift assay showed the ability of the obtained MNT to interact with the N-protein in A431 cells transfected with the SARS-CoV-2 N-protein fused to the mRuby3 fluorescent protein.

About the authors

Y. V. Khramtsov

Institute of Gene Biology, RAS

Email: alsobolev@yandex.ru
Russian Federation, Moscow

A. V. Ulasov

Institute of Gene Biology, RAS

Email: alsobolev@yandex.ru
Russian Federation, Moscow

T. N. Lupanova

Institute of Gene Biology, RAS

Email: alsobolev@yandex.ru
Russian Federation, Moscow

G. P. Georgiev

Institute of Gene Biology, RAS

Email: alsobolev@yandex.ru
Russian Federation, Moscow

A. S. Sobolev

Institute of Gene Biology, RAS; Lomonosov Moscow State University

Author for correspondence.
Email: alsobolev@yandex.ru
Russian Federation, Moscow; Russian Federation, Moscow

References

  1. Clercq E.D., Li G. // Clin Microbiol Rev. 2016. V. 29. P. 695–747. https://doi.org/10.1128/CMR.00102-15
  2. Gebauer M., Skerra A. // Annu Rev Pharmacol Toxicol. 2020. V. 60. P. 391–415.
  3. Surjit M., Lal S.K. // Infect Genet Evol. 2008. V. 8. P. 397–405.
  4. Wu C., Zheng M. // Preprints. 2020. 2020020247.
  5. Prajapat M., Sarma P., Shekhar N., et al. // Indian J Pharmacol. 2020. V. 52. P. 56.
  6. Du Y., Zhang T., Meng X., et al. // Preprints. 2020.
  7. Sobolev A.S. // Front Pharmacol. 2018. V. 9, 952.
  8. Khramtsov Y.V., Vlasova A.D., Vlasov A.V., et al. // Acta Cryst. 2020. V. D76. P. 1270–1279.
  9. Slastnikova T.A., Rosenkranz A.A., Khramtsov Y.V., et al. // Drug Des Devel Ther. 2017. V. 11. P. 1315–1334.
  10. Li G., Li W., Fang X., et al. // Protein Expr Purif. 2021. V. 186.
  11. Kern H.B., Srinivasan S., Convertine A.J., et al. // Mol Pharmaceutics. 2017. V. 14 (5). P. 1450–1459.
  12. Khramtsov Y.V., Ulasov A.V., Lupanova T.N. et al. // Dokl Biochem Biophys. 2022. V. 506. P. 220–222.
  13. Molina D.M., Jafari R., Ignatushchenko M., et al. // Science. 2013. V. 341. P. 84–87.
  14. Liao H.-I., Olson C.A., Hwang S., et al. // J Biol Chem. 2009. V. 284. P. 17512–17520.

Supplementary files

Supplementary Files
Action
1. JATS XML
2.

Download (439KB)
3.

Download (76KB)
4.

Download (94KB)

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies